121 related articles for article (PubMed ID: 30429020)
1. A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.
Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Sato A; Tsujimura T; Ueda H; Makihata S; Kato F; Iwasaki A; Nabeshima K
Lung Cancer; 2018 Nov; 125():198-204. PubMed ID: 30429020
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Immunohistochemistry, Next-generation Sequencing and Fluorescence In Situ Hybridization for Detection of MTAP Loss in Pleural Mesothelioma.
Febres-Aldana CA; Chang JC; Jungbluth AA; Adusumilli PS; Bodd FM; Frosina D; Geronimo JA; Hernandez E; Irawan H; Offin MD; Rekhtman N; Travis WD; Vanderbilt C; Zauderer MG; Zhang Y; Ladanyi M; Yang SR; Sauter JL
Mod Pathol; 2024 Mar; 37(3):100420. PubMed ID: 38185249
[TBL] [Abstract][Full Text] [Related]
3. BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas.
Leblay N; Leprêtre F; Le Stang N; Gautier-Stein A; Villeneuve L; Isaac S; Maillet D; Galateau-Sallé F; Villenet C; Sebda S; Goracci A; Byrnes G; McKay JD; Figeac M; Glehen O; Gilly FN; Foll M; Fernandez-Cuesta L; Brevet M
J Thorac Oncol; 2017 Apr; 12(4):724-733. PubMed ID: 28034829
[TBL] [Abstract][Full Text] [Related]
4. Investigation of MTAP and BAP1 staining loss and P16/CDKN2A deletion in pleural cytology specimens and its role in the diagnosis of mesothelioma.
Şeker NS; Tekin E; Ak G; Metintaş M; Metintaş S; Dündar E
Diagn Cytopathol; 2024 Apr; 52(4):211-216. PubMed ID: 38243885
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic performance of immunohistochemistry markers for malignant pleural mesothelioma diagnosis and subtypes. A systematic review and meta-analysis.
Parra-Medina R; Castañeda-González JP; Chaves-Cabezas V; Alzate JP; Chaves JJ
Pathol Res Pract; 2024 May; 257():155276. PubMed ID: 38603842
[TBL] [Abstract][Full Text] [Related]
6. Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes.
Churg A; Nabeshima K; Ali G; Bruno R; Fernandez-Cuesta L; Galateau-Salle F
Lung Cancer; 2018 Oct; 124():95-101. PubMed ID: 30268487
[TBL] [Abstract][Full Text] [Related]
7. Loss of MTAP expression by immunohistochemistry is a surrogate marker for homozygous 9p21.3 deletion in urothelial carcinoma.
Vlajnic T; Chijioke O; Roma L; Savic Prince S; Zellweger T; Rentsch CA; Bubendorf L
Mod Pathol; 2024 Apr; ():100495. PubMed ID: 38641323
[TBL] [Abstract][Full Text] [Related]
8. Malignant mesothelioma of the pleura with desmoplastic histology: a case series and literature review.
Hashimoto K; Okuma Y; Hosomi Y; Hishima T
BMC Cancer; 2016 Sep; 16(1):718. PubMed ID: 27599565
[TBL] [Abstract][Full Text] [Related]
9. Mesothelioma: morphologic and immunohistochemical findings.
Churg A
Pathologie (Heidelb); 2024 Apr; ():. PubMed ID: 38568257
[TBL] [Abstract][Full Text] [Related]
10. BAP1, Wilms' tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma.
Yuce TH; Ak G; Metintas S; Dundar E; Roe OD; Panou V; Metintas M
J Cancer Res Clin Oncol; 2024 Jan; 150(2):38. PubMed ID: 38280040
[TBL] [Abstract][Full Text] [Related]
11. Reliably making the primary diagnosis of mesothelioma utilizing serous fluid cytology specimens: an institutional experience.
Jones TE; Geisler DL; Baskota SU; Ohori NP; Cuda J; Khader SN
J Am Soc Cytopathol; 2024; 13(3):174-182. PubMed ID: 38514361
[TBL] [Abstract][Full Text] [Related]
12. [Expression and prognostic significance of KAP1 gene in malignant pleural mesothelioma].
Mei W; Wang XM; Liu RA; Xiong W; Zhang YP
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2024 Apr; 42(4):258-267. PubMed ID: 38677988
[No Abstract] [Full Text] [Related]
13. Reliability assessment of methylthioadenosine phosphorylase immunohistochemistry as a surrogate biomarker for CDKN2A homozygous deletion in adult-type IDH-mutant diffuse gliomas.
Gundogdu F; Babaoglu B; Soylemezoglu F
J Neuropathol Exp Neurol; 2024 Jan; 83(2):107-114. PubMed ID: 38109891
[TBL] [Abstract][Full Text] [Related]
14. Detailed clinical course of a patient with rapidly progressing sarcomatoid pleural mesothelioma without p16 deletion with systemic haematogenous metastasis to soft tissues.
Mizuhashi K; Okamoto K; Nabeshima K; Kishimoto T
BMJ Case Rep; 2024 Feb; 17(2):. PubMed ID: 38341199
[TBL] [Abstract][Full Text] [Related]
15. Molecular and Immunohistochemical Testing in Mesothelioma and Other Mesothelial Lesions.
Hung YP; Chirieac LR
Arch Pathol Lab Med; 2024 May; 148(5):e77-e89. PubMed ID: 38190277
[TBL] [Abstract][Full Text] [Related]
16. Guidelines for Pathologic Diagnosis of Mesothelioma.
Husain AN; Chapel DB; Attanoos R; Beasley MB; Brcic L; Butnor K; Chirieac LR; Churg A; Dacic S; Galateau-Salle F; Hiroshima K; Hung YP; Klebe S; Krausz T; Khoor A; Litzky L; Marchevsky A; Nabeshima K; Nicholson AG; Pavlisko EN; Roden AC; Roggli V; Sauter JL; Schulte JJ; Sheaff M; Travis WD; Tsao MS; Walts AE; Colby TV
Arch Pathol Lab Med; 2024 Apr; ():. PubMed ID: 38586983
[TBL] [Abstract][Full Text] [Related]
17. Combined Inhibition of EZH2 and FGFR is Synergistic in BAP1-deficient Malignant Mesothelioma.
Badhai J; Landman N; Pandey GK; Song JY; Hulsman D; Krijgsman O; Chandrasekaran G; Berns A; van Lohuizen M
Cancer Res Commun; 2024 Jan; 4(1):18-27. PubMed ID: 38054839
[TBL] [Abstract][Full Text] [Related]
18. BAP1 Deficiency Inflames the Tumor Immune Microenvironment and Is a Candidate Biomarker for Immunotherapy Response in Malignant Pleural Mesothelioma.
Xu D; Gao Y; Yang H; Spils M; Marti TM; Losmanová T; Su M; Wang W; Zhou Q; Dorn P; Shu Y; Peng RW
JTO Clin Res Rep; 2024 May; 5(5):100672. PubMed ID: 38715965
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center.
Galateau Salle F; Le Stang N; Tirode F; Courtiol P; Nicholson AG; Tsao MS; Tazelaar HD; Churg A; Dacic S; Roggli V; Pissaloux D; Maussion C; Moarii M; Beasley MB; Begueret H; Chapel DB; Copin MC; Gibbs AR; Klebe S; Lantuejoul S; Nabeshima K; Vignaud JM; Attanoos R; Brcic L; Capron F; Chirieac LR; Damiola F; Sequeiros R; Cazes A; Damotte D; Foulet A; Giusiano-Courcambeck S; Hiroshima K; Hofman V; Husain AN; Kerr K; Marchevsky A; Paindavoine S; Picquenot JM; Rouquette I; Sagan C; Sauter J; Thivolet F; Brevet M; Rouvier P; Travis WD; Planchard G; Weynand B; Clozel T; Wainrib G; Fernandez-Cuesta L; Pairon JC; Rusch V; Girard N
J Thorac Oncol; 2020 Jun; 15(6):1037-1053. PubMed ID: 32165206
[TBL] [Abstract][Full Text] [Related]
20. Molecular prognostication in grade 3 meningiomas and p16/MTAP immunohistochemistry for predicting
Tosefsky K; Martin KC; Rebchuk AD; Wang JZ; Nassiri F; Lum A; Zadeh G; Makarenko S; Yip S
Neurooncol Adv; 2024; 6(1):vdae002. PubMed ID: 38288091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
